baricitinib · Olumiant

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Alopecia Areata, COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Atopic Dermatitis · Phase 3 · investigational in the US

Also approved (6)
CA
  • OLUMIANT (baricitinib tablets) is indicated for: Rheumatoid Arthritis (RA) • In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT may be used as monotherapy in cases of intolerance to MTX. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND...
Product first approved 2018Health Canada
JP
  • Rheumatoid arthritis with inadequate response to standard of care (2 mg and 4 mg tablets)
Product first approved 2017pharmaceuticalprocessingworld.com
EU
  • Olumiant: moderate to severe active rheumatoid arthritis in adults; holder Eli Lilly Nederland B.V.EMA
  • Moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy (Olumiant)EMA
  • Treatment of active juvenile idiopathic arthritis in patients 2 years of age and older (Olumiant)Outside this platform's coverageEMA
  • Treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older (Olumiant)EMA
Product first approved 2017

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Alopecia Areata
NCT05723198 · Eli Lilly and Company
2023-02-27 – 2033-09 · Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
What this study did
Atopic Dermatitis
NCT03952559 · Eli Lilly and Company
2019-05-24 – 2026-05-22 · Atopic Dermatitis
What this study did
NCT03334435 · Eli Lilly and Company
2018-03-28 – 2023-07-12 · Atopic Dermatitis
What this study did
NCT03559270 · Eli Lilly and Company
2018-06-27 – 2022-06-13 · Atopic Dermatitis
What this study did
NCT03435081 · Eli Lilly and Company
2018-02-20 – 2021-08-16 · Atopic Dermatitis
What this study did
NCT03733301 · Eli Lilly and Company
2018-11-16 – 2019-08-22 · Atopic Dermatitis
What this study did
COVID-19
NCT04381936 · University of Oxford
2020-03-19 – 2038-09-30 · Pneumonia
What this study did
NCT05858515 · Vanderbilt University Medical Center
2024-10-21 – 2029-12-30 · Post-Acute COVID-19 Syndrome
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT06631287 · Wes Ely
2024-10-21 – 2027-07-01 · Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
What this study did
NCT05056558 · Incepta Pharmaceuticals Ltd
2020-07-30 – 2026-04-12 · Covid19
What this study did
NCT05074420 · Eli Lilly and Company
2021-12-21 – 2024-11-04 · Covid19, Corona Virus Infection
What this study did
NCT04890626 · Instituto de Investigación Hospital Universitario La Paz
2020-04-04 – 2023-07-17 · SARS-CoV-2 Infection
What this study did
NCT04832880 · ASST Fatebenefratelli Sacco
2021-04-06 – 2022-12 · Covid19
What this study did
NCT04970719 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
2021-07-10 – 2021-12 · COVID-19 Pneumonia
What this study did
NCT04640168 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-12-02 – 2021-06-18 · COVID-19
What this study did
NCT04693026 · M Abdur Rahim Medical College and Hospital
2020-09-10 – 2021-03-05 · Covid19, Covid-19 ARDS
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT04870203 · University Hospital, Bordeaux
2021-07-15 – 2027-03 · Rheumatoid Arthritis
What this study did
NCT03701789 · University of Erlangen-Nürnberg Medical School
2018-09-11 – 2021-10-11 · Rheumatoid Arthritis, Bone Density, Finger Joints
What this study did
NCT01885078 · Eli Lilly and Company
2013-06-27 – 2020-11-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07543458 · Oxford University Clinical Research Unit, Vietnam
2026-10-01 – 2031-07-31 · Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
What this study did
NCT07222137 · Eli Lilly and Company
2026-01-12 – 2031-07 · Diabetes Mellitus, Type 1
What this study did
NCT03773965 · Eli Lilly and Company
2019-04-05 – 2031-07 · Juvenile Idiopathic Arthritis
What this study did
NCT05651880 · University Hospital, Rouen
2026-07 – 2029-12 · Active Non-anterior Non-infectious Uveitis
What this study did
NCT07279688 · University Hospital, Brest
2025-12-18 – 2029-06 · Polymyalgia Rheumatica (PMR)
What this study did
NCT07222332 · Eli Lilly and Company
2026-02-05 – 2028-07 · Diabetes Mellitus, Type 1
What this study did
NCT04972760 · Assistance Publique - Hôpitaux de Paris
2022-08-31 – 2028-02-28 · Dermatomyositis
What this study did
NCT04088396 · Eli Lilly and Company
2020-02-12 – 2026-10 · Systemic Juvenile Idiopathic Arthritis
What this study did
NCT06936215 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2024-01-01 – 2025-05 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT03843125 · Eli Lilly and Company
2019-09-09 – 2022-04-01 · Systemic Lupus Erythematosus
What this study did
NCT03616912 · Eli Lilly and Company
2018-08-02 – 2022-03-09 · Systemic Lupus Erythematosus
What this study did
NCT03773978 · Eli Lilly and Company
2018-12-17 – 2022-01-26 · Juvenile Idiopathic Arthritis
What this study did
Phase 2/3 (11)
Alopecia Areata
COVID-19
NCT04891133 · Oslo University Hospital
2021-06-03 – 2023-01-23 · COVID-19, Emerging Infectious Disease
What this study did
NCT04340232 · University of Colorado, Denver
2021-03 – 2021-10 · COVID-19
What this study did
NCT04320277 · Hospital of Prato
2020-05-16 – 2020-07-30 · Pharmacological Action
What this study did
NCT04358614 · Fabrizio Cantini
2020-03-16 – 2020-04-07 · COVID, Pneumonia
What this study did
Other / comorbidity
NCT07449910 · The First Affiliated Hospital of University of Science and Technology of China
2026-03-17 – 2028-01-31 · Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib
What this study did
NCT06475820 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2023-12-01 – 2027-04-01 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
What this study did
NCT05914584 · Nantes University Hospital
2023-07-01 – 2025-12-31 · Hospital-acquired Pneumonia
What this study did
NCT06768840 · South Valley University
2024-10-02 – 2025-10 · Vitiligo, Generalized
What this study did
NCT04517253 · Eli Lilly and Company
2020-10-27 – 2024-11-28 · Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
What this study did
NCT05686746 · Assiut University
2022-06-01 – 2023-08-01 · Lupus or SLE, Nephritis
What this study did
Phase 2 (55)
Alopecia Areata
NCT06797310 · National Taiwan University Hospital
2025-01-23 – 2026-12-31 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT02576938 · Eli Lilly and Company
2016-02 – 2017-03 · Atopic Dermatitis
What this study did
COVID-19
NCT04321993 · Lisa Barrett
2020-04-17 – 2024-04 · COVID-19
What this study did
NCT04346147 · Hospital Universitario de Fuenlabrada
2020-05-07 – 2021-09 · COVID-19 Pneumonia
What this study did
NCT04373044 · University of Southern California
2020-05-01 – 2021-05-12 · Symptomatic COVID-19 Infection Laboratory-Confirmed
What this study did
NCT04399798 · Fondazione IRCCS Policlinico San Matteo di Pavia
2020-05-15 – 2020-11-15 · Corona Virus Infection
What this study did
NCT04393051 · Azienda Ospedaliero, Universitaria Pisana
2020-05-20 – 2020-07-30 · Covid-19, SARS-CoV 2, SARS Pneumonia
What this study did
Rheumatoid Arthritis
NCT03755466 · Shinshu University
2018-11-21 – 2025-11-20 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07081763 · ANRS, Emerging Infectious Diseases
2027-05 – 2033-05 · HIV-1-infection
What this study did
NCT06381661 · Assistance Publique - Hôpitaux de Paris
2026-07-09 – 2031-07-09 · Sepsis
What this study did
NCT06923072 · National Heart, Lung, and Blood Institute (NHLBI)
2026-02-18 – 2030-12-15 · Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
What this study did
NCT07779642 · University of Colorado, Denver
2026-09 – 2030-09 · ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure
What this study did
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT07003997 · Emory University
2025-09-03 – 2030-02 · Major Depressive Disorder
What this study did
NCT06868381 · Stanford University
2026-04-01 – 2028-12-01 · Cardiac Sarcoidosis
What this study did
NCT06490757 · Assistance Publique - Hôpitaux de Paris
2024-10-02 – 2028-09-02 · Inflammatory Hepatocellular Adenoma
What this study did
NCT07669675 · Peking University People's Hospital
2026-07-01 – 2028-08-31 · ITP - Immune Thrombocytopenia
What this study did
NCT06849908 · Peking Union Medical College Hospital
2024-11-08 – 2028-06-30 · Behcet Syndrome, Intestinal Type
What this study did
NCT05452564 · William Tyor
2023-05-18 – 2028-01 · Human Immunodeficiency Virus
What this study did
NCT07209267 · Emory University
2026-12 – 2028-01 · HIV Infection, HIV
What this study did
NCT05849038 · Emory University
2023-12-11 – 2027-11 · HIV, Depression, Anhedonia
What this study did
NCT07608796 · Emory University
2026-10 – 2027-10 · Depressive Symptoms, Cognitive Symptom
What this study did
NCT06439615 · Tang-Du Hospital
2024-08-01 – 2027-06-30 · Spontaneous Subarachnoid Hemorrhage
What this study did
NCT06768294 · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
2025-01 – 2027-01 · Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
What this study did
NCT06065046 · Tang-Du Hospital
2023-11-24 – 2026-12-31 · Traumatic Brain Injury
What this study did
NCT06158113 · University of North Carolina, Chapel Hill
2024-03-13 – 2026-09-09 · Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
What this study did
NCT07028385 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2025-09-22 – 2026-06-30 · HIV
What this study did
NCT07843732 · Raven Clinical Research
2024-10-22 – 2026-04-28 · Central Centrifugal Cicatricial Alopecia
What this study did
NCT05237388 · Duke University
2023-04-20 – 2026-04-03 · Chronic Kidney Diseases
What this study did
NCT05524311 · Assistance Publique - Hôpitaux de Paris
2022-11-10 – 2026-01-02 · Juvenile Dermatomyositis
What this study did
NCT05852171 · First Affiliated Hospital of Zhejiang University
2023-05-04 – 2025-12-31 · Mastitis Chronic, Idiopathic Granulomatous Mastitis
What this study did
NCT06737705 · De-zhi Kang
2025-01-01 – 2025-08-18 · Intracerebral Hemorrhage
What this study did
NCT05932524 · Peking University People's Hospital
2023-07-07 – 2025-06 · Immune Thrombocytopenia
What this study did
NCT04901325 · Oregon Health and Science University
2023-10-03 – 2025-05-07 · Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
What this study did
NCT05852847 · Peking University People's Hospital
2023-05-16 – 2025-05 · Immune Thrombocytopenia
What this study did
NCT06114407 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-10-30 – 2024-12-30 · Spondyloarthritis, Axial
What this study did
NCT05016297 · Peking Union Medical College Hospital
2022-07-14 – 2024-11-22 · Sjogren's Syndrome
What this study did
NCT06662721 · Liu Tian
2023-04-03 – 2024-06-08 · Takayasu Arteritis
What this study did
NCT04774224 · St Vincent's Institute of Medical Research
2020-10-30 – 2024-05-06 · Type 1 Diabetes
What this study did
NCT03921554 · Adeline Vanderver, MD
2019-06-03 – 2024-03-25 · Aicardi Goutieres Syndrome
What this study did
NCT05446831 · Peking University People's Hospital
2022-07-13 – 2023-12-01 · ITP, Immune Thrombocytopenia
What this study did
NCT04208464 · University of Manchester
2021-10-07 – 2023-09-25 · Idiopathic Inflammatory Myopathies
What this study did
NCT05263505 · Washington University School of Medicine
2022-02-21 – 2023-09-11 · Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
What this study did
NCT04027101 · University Hospital, Brest
2020-12-01 – 2023-08-30 · Polymyalgia Rheumatic (PMR)
What this study did
NCT05188521 · Aaron R. Mangold
2022-01-11 – 2023-05-17 · Cutaneous Lichen Planus
What this study did
NCT04822584 · University Hospital, Bordeaux
2021-07-16 – 2023-04-26 · Vitiligo
What this study did
NCT05361109 · University of Washington
2022-06-01 – 2023-03-31 · Dermatomyositis
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT07535645 · Peking University People's Hospital
2026-03-09 – 2029-09-15 · Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
NCT06548802 · Tianjin Medical University General Hospital
2024-02-29 – 2026-12-31 · Pulmonary Injury After Intracerebral Hemorrhage
What this study did
NCT05189106 · Massachusetts General Hospital
2022-12-05 – 2025-06-20 · Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
What this study did
NCT02759731 · National Cancer Institute (NCI)
2016-11-01 – 2024-05-30 · Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
What this study did
NCT04916756 · Peking Union Medical College Hospital
2020-01-16 – 2021-03-25 · Sjogren's Syndrome
What this study did
Phase 1 (24)
Alopecia Areata
NCT06545110 · South Valley University
2023-09-01 – 2024-10-30 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT07262983 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-11-24 – 2030-10-01 · Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
What this study did
Rheumatoid Arthritis
NCT01398475 · Eli Lilly and Company
2011-07 – 2011-09 · Chronic Inflammatory Disorder, Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT05792462 · Tianjin Medical University General Hospital
2023-04-15 – 2027-03-01 · NMO Spectrum Disorder
What this study did
NCT07843693 · AbbVie
2026-08-26 – 2026-12 · Healthy Volunteers
What this study did
NCT03945760 · Wright State Physicians
2020-09-14 – 2023-10-16 · Allergic Contact Dermatitis
What this study did
NCT04131738 · Washington University School of Medicine
2020-04-07 – 2022-08-17 · Graft-versus-host-disease, Graft Vs Host Disease
What this study did
NCT03212638 · Eli Lilly and Company
2017-06-27 – 2017-11-01 · Healthy
What this study did
NCT02758613 · Eli Lilly and Company
2016-05 – 2016-07 · Healthy
What this study did
NCT02340104 · Eli Lilly and Company
2015-01 – 2015-02 · Healthy Volunteers
What this study did
NCT02263911 · Eli Lilly and Company
2014-11 – 2014-12 · Healthy Participants
What this study did
NCT01968057 · Eli Lilly and Company
2013-10 – 2013-12 · Healthy Volunteers
What this study did
NCT01960140 · Eli Lilly and Company
2013-10 – 2013-12 · Healthy Volunteers
What this study did
NCT01924299 · Eli Lilly and Company
2013-08 – 2013-11 · Healthy Volunteers
What this study did
NCT01937026 · Eli Lilly and Company
2013-09 – 2013-11 · Healthy Volunteers
What this study did
NCT01925144 · Eli Lilly and Company
2013-10 – 2013-11 · Healthy Volunteers
What this study did
NCT01896726 · Eli Lilly and Company
2013-07 – 2013-10 · Healthy Volunteers
What this study did
NCT01910311 · Eli Lilly and Company
2013-08 – 2013-10 · Healthy Volunteers
What this study did
NCT01859078 · Eli Lilly and Company
2013-05 – 2013-08 · Healthy Volunteers
What this study did
NCT01870388 · Eli Lilly and Company
2013-06 – 2013-07 · Liver Diseases, Hepatic Insufficiency
What this study did
NCT01536951 · Eli Lilly and Company
2012-02 – 2013-05 · Healthy Participants
What this study did
NCT01247350 · Eli Lilly and Company
2010-11 – 2011-04 · Healthy Volunteer
What this study did
NCT01299285 · Eli Lilly and Company
2011-02 – 2011-03 · Healthy Volunteers
What this study did
Phase 4 (12)
COVID-19
NCT04390464 · Cambridge University Hospitals NHS Foundation Trust
2020-05-08 – 2022-05-01 · COVID19
What this study did
Rheumatoid Arthritis
NCT06687551 · University Hospital, Toulouse
2025-06-06 – 2029-04-01 · Rheumatoid Arthritis (RA
What this study did
NCT07357649 · Tanta University
2026-01 – 2026-12 · Rheumatoid Arthritis
What this study did
NCT05955066 · Chinese University of Hong Kong
2023-12-01 – 2026-06 · Rheumatoid Arthritis
What this study did
NCT03915964 · Eli Lilly and Company
2019-04-25 – 2025-05-28 · Rheumatoid Arthritis
What this study did
NCT04086745 · Eli Lilly and Company
2020-02-14 – 2025-05-19 · Rheumatoid Arthritis
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT05827497 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-04-01 – 2024-03-31 · Rheumatoid Arthritis
What this study did
NCT05660655 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2022-10-01 – 2023-09-30 · Rheumatoid Arthritis
What this study did
NCT05238896 · Assistance Publique - Hôpitaux de Paris
2022-06-27 – 2023-03-31 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05300932 · Tongji Hospital
2022-03-08 – 2026-11-12 · Systemic Sclerosis
What this study did
NCT06240351 · University of Alabama at Birmingham
2024-04-22 – 2026-09-16 · Frontal Fibrosing Alopecia
What this study did
Early phase / not applicable (7)
Alopecia Areata
NCT07645430 · Benha University
2023-01-01 – 2026-06-09 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT05969730 · Mazandaran University of Medical Sciences
2023-08-15 – 2025-11-14 · Atopic Dermatitis
What this study did
COVID-19
NCT05279391 · Democritus University of Thrace
2020-10-25 – 2023-12-31 · COVID-19 Severe Respiratory Failure
What this study did
NCT05082714 · University Hospital of Patras
2021-10-20 – 2022-06-04 · COVID-19
What this study did
Rheumatoid Arthritis
NCT05003310 · Galvani Bioelectronics
2021-10-19 – 2032-04 · Rheumatoid Arthritis
What this study did
NCT06977035 · Sohag University
2025-05-05 – 2026-06 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05781516 · Wen Zhang
2023-01-20 – 2025-06 · IgG4-related Disease With Eosinophilia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Alopecia Areata
NCT07554222 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-18 – 2028-12-31 · Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT05897372 · Iain Bressendorff
2023-08-01 – 2024-09-23 · Diabetic Kidney Disease
What this study did

Competitive landscape

This mechanism is crowded: 9 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Baricitinib (Olumiant): this drugApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
Ruxolitinib (Jakafi)
Approved(overall)
Small moleculeJAK1/2
Partial signal(overall)
No reviewed efficacy summary in this indication
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Ivarmacitinib
Phase 3(overall)
Small moleculeJAK
not yet graded(overall)
No reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
BMS-986454Phase 1—PAD4 (peptidylarginine deiminase 4)not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND261Phase 1Biologic (subtype unspecified)CD20 x CD3not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 20 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Olumiant (baricitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-12 · NCT07843693 · CT.gov ↗
What to watch
Phase 1/2Pulmonary Injury After Intracerebral HemorrhageActive not recruiting
Est. primary completion 2026-12-31 · NCT06548802 · CT.gov ↗
What to watch
Phase 2Spontaneous Subarachnoid HemorrhageNot yet recruiting
Est. primary completion 2026-12-31 · NCT06439615 · CT.gov ↗
What to watch
2027 (9)
March 2027 (2)
Phase 3Rheumatoid ArthritisActive not recruiting
Est. primary completion 2027-03 · NCT04870203 · CT.gov ↗
What to watch
Phase 1NMO Spectrum DisorderActive not recruiting
Est. primary completion 2027-03-01 · NCT05792462 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Behcet Syndrome, Intestinal TypeRecruiting
Est. primary completion 2027-06-30 · NCT06849908 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicableRheumatoid ArthritisRecruiting
Est. primary completion 2027-07 · NCT05003310 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, BaricitinibNot yet recruiting
Est. primary completion 2027-08-17 · NCT07449910 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Depressive Symptoms, Cognitive SymptomRecruiting
Est. primary completion 2027-10 · NCT07608796 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2HIV, Depression, AnhedoniaRecruiting
Est. primary completion 2027-11 · NCT05849038 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell TransplantationRecruiting
Est. primary completion 2027-12-31 · NCT07535645 · CT.gov ↗
What to watch
Phase 2ITP - Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07669675 · CT.gov ↗
What to watch
2028 (12)
January 2028 (2)
Phase 2Human Immunodeficiency VirusRecruiting
Est. primary completion 2028-01 · NCT05452564 · CT.gov ↗
What to watch
Phase 2HIV Infection, HIVNot yet recruiting
Est. primary completion 2028-01 · NCT07209267 · CT.gov ↗
What to watch
February 2028 (1)
Phase 3DermatomyositisRecruiting
Est. primary completion 2028-02-28 · NCT04972760 · CT.gov ↗
What to watch
March 2028 (2)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 3Alopecia AreataRecruiting
Est. primary completion 2028-03 · NCT05723198 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3COVID-19Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2028-07 · NCT07222332 · CT.gov ↗
What to watch
Phase 2Cardiac SarcoidosisRecruiting
Est. primary completion 2028-07-01 · NCT06868381 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2SepsisRecruiting
Est. primary completion 2028-08-09 · NCT06381661 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Inflammatory Hepatocellular AdenomaRecruiting
Est. primary completion 2028-09-02 · NCT06490757 · CT.gov ↗
What to watch
Phase 3COVID-19Recruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Polymyalgia Rheumatica (PMR)Recruiting
Est. primary completion 2028-11 · NCT07279688 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2029-04-01 · NCT06687551 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2HIV-1-infectionNot yet recruiting
Est. primary completion 2029-05 · NCT07081763 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory FailureNot yet recruiting
Est. primary completion 2029-09 · NCT07779642 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Active Non-anterior Non-infectious UveitisNot yet recruiting
Est. primary completion 2029-12 · NCT05651880 · CT.gov ↗
What to watch
2030 (4)
February 2030 (1)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2030-02 · NCT07003997 · CT.gov ↗
What to watch
May 2030 (1)
Phase 1Atopic DermatitisRecruiting
Est. primary completion 2030-05-01 · NCT07262983 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections …Not yet recruiting
Est. primary completion 2030-07-31 · NCT07543458 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant AtrophicRecruiting
Est. primary completion 2030-12-14 · NCT06923072 · CT.gov ↗
What to watch
2031 (2)
July 2031 (2)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2031-07 · NCT07222137 · CT.gov ↗
What to watch
Phase 3Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2031-07 · NCT03773965 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 September 2026ApprovalFDA approves Olumiant for adolescents with severe alopecia areata
US, FDA · Eli Lilly and Company · Source ↗
27 February 2026Filing submittedOlumiant US submission for adolescent severe alopecia areata
US, FDA · Source ↗